Population Pharmacokinetic Analysis of Panitumumab in Patients With Advanced Solid Tumors
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Panitumumab is a fully human monoclonal antibody targeted to the extracellular domain of human epidermal growth factor receptor (EGFR). A comprehensive population pharmacokinetic model of panitumumab was developed using nonlinear mixed‐effects modeling of 1200 patients with advanced solid tumors in 14 clinical studies. The disposition of panitumumab was best described with a 2‐compartment model with parallel linear and nonlinear (Michaelis‐Menten) elimination pathways. For a typical male patient with colorectal cancer (80 kg, 60 years old), the estimates for the linear clearance (CL), the maximum nonlinear clearance (V max/K m), the central volume of distribution (V 1), the peripheral volume of distribution (V 2), and the Michaelis‐Menten constantt (K m) are 0.273 L/d, 28.4 L/d, 3. 95 L, 2.59 L, and 0.426 mcg/mL, respectively. Baseline covariates such as body weight, cancer type, age, sex, and race were studied for their influence on panitumumab pharmacokinetics. Body weight was found to be the most influential covariate on panitumumab exposure, affecting CL, V max, and V 1. The administration of concomitant chemotherapy (IFL, FOLFIRI, or paclitaxel/carboplatin) or intensity of baseline tumor EGFR expression did not alter the pharmacokinetics of panitumumab. The presence of antipanitumumab antibodies in patients (immunogenicity rate 3.4%) did not appear to affect panitumumab exposure substantially (AUC difference 8%). In support of a new drug application in Japan, the model was used to assess panitumumab pharmacokinetics in Japanese patients compared to other racial groups; there were no significant differences in model‐predicted steady‐state panitumumab AUC, C max, or C min after accounting for the effect of body weight.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035 · cited 1×
“Moreover, clinical study data showed that neither response rate nor progression-free survival was correlated with the intensity and extent of tumor EGFR staining.(23) Instead, the absence of receptor mutations in KRAS and BRAF was a more relevant predictor of response rates to antibodies directed against EGFR.”
BackgroundK-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Linardou, H., Dahabreh, I. J., Kanaloupiti, D., Siannis, F., Bafaloukos, D., Kosmidis, P., Papadimitriou, C. A., & Murray, S. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70206-7 · Cited by 739
Approximations of the Target-Mediated Drug Disposition Model and Identifiability of Model Parameters
Gibiansky, L., Gibiansky, E., Kakkar, T., & Ma, P. (2008) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-008-9102-8 · Cited by 272 · cited 1×
“A more theoretical derivation shows that Km is approximately equal to KD + kint/kon, where kint is the rate of drug-receptor internalization, in a model with both first-order and Michaelis-Menten elimination pathways approximating a full model of target-mediated drug disposition.(20) Therefore, it is expected that Km…”
MethodSelf-citationGreen, L. L. (1999) · Journal of Immunological Methods · doi:10.1016/s0022-1759(99)00137-4 · Cited by 229 · cited 2×
“The most rational approach to overcome this limitation is through fully human monoclonal antibodies obtained either by selection from phage display libraries of immunoglobulin genes27 or from mouse strains genetically engineered to produce fully human antibodies when sensitized to an immunogen such as the XenoMouse.28…”
Background
Cited by
Pharmacokinetics of Monoclonal Antibodies
Ryman, J. T., & Meibohm, B. (2017) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12224 · Cited by 802
Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
Keizer, R. J., Huitema, A. D. R., Schellens, J. H. M., & Beijnen, J. H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11531280-000000000-00000 · Cited by 725
Population Pharmacokinetics of Therapeutic Monoclonal Antibodies
Dirks, N. L., & Meibohm, B. (2010) · Clinical Pharmacokinetics · doi:10.2165/11535960-000000000-00000 · Cited by 500
Gender medicine and oncology: report and consensus of an ESMO workshop
Wagner, A. D., Oertelt-Prigione, S., Adjei, A., Buclin, T., Cristina, V., Csajka, C., Coukos, G., Dafni, U., Dotto, G.-P., Ducreux, M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz414 · Cited by 214
Fixed Dosing of Monoclonal Antibodies in Oncology
Hendrikx, J. J. M. A., Haanen, J. B. A. G., Voest, E. E., Schellens, J. H. M., Huitema, A. D. R., & Beijnen, J. H. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0167 · Cited by 168
Metadata
- Authors
- Ma, P., Yang, B., Wang, Y., Peterson, M., Narayanan, A., Sutjandra, L., Rodriguez, R., & Chow, A.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2009-10
- Volume
- 49
- Issue
- 10
- Pages
- 1142-1156
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2061914417
- Cited by
- 89
- References
- 6
- FWCI
- 4.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.